Advertisement

August 7, 2019

Perfuze's Millipede CIS Technology Receives Breakthrough Device Designation From FDA

August 7, 2019—Perfuze, Ltd, a developer of next-generation catheter-based technology to treat acute ischemic stroke, announced that the FDA has granted Breakthrough Device designation for the company's Millipede clot ingestion system (CIS) technology.

The catheter-based Millipede CIS is designed to remove clots from the brain after acute ischemic stroke.

FDA Breakthrough Device designation is granted to certain medical devices that provide a more effective treatment of life-threatening or irreversibly debilitating diseases. The designation recognizes the novelty of the Millipede technology and its potential to offer significant advantages over existing alternatives for treatment of acute ischemic stroke, noted Perfuze. The company is headquartered in Galway, Ireland.

Advertisement


August 8, 2019

Siemens Healthineers to Acquire Corindus Vascular Robotics

August 7, 2019

FDA Issues Updated Statement on the Use of Paclitaxel Devices to Treat PAD